Arcus Biosciences (RCUS) Change in Acquisitions & Divestments (2017 - 2026)

Arcus Biosciences' Change in Acquisitions & Divestments history runs 10 years deep, the most recent figure standing at $257.0 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 28.61% year-over-year to $257.0 million in Q1 2026; TTM through Mar 2026 was $970.0 million, a 9.09% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 15.5% from the prior year.
• Change in Acquisitions & Divestments grew to $257.0 million in Q1 2026 per RCUS's latest filing, from $215.0 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $360.0 million in Q1 2025 and bottomed at $94.0 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $242.0 million (2024), against an average of $231.5 million.
• Across the five-year window, Change in Acquisitions & Divestments tumbled 62.6% in 2022 and soared 202.13% in 2023, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $203.0 million in 2022, then decreased by 28.57% to $145.0 million in 2023, then surged by 40.0% to $203.0 million in 2024, then advanced by 5.91% to $215.0 million in 2025, then climbed by 19.53% to $257.0 million in 2026.
• Per Business Quant, the three latest RCUS Change in Acquisitions & Divestments figures stand at $257.0 million (Q1 2026), $215.0 million (Q4 2025), and $243.0 million (Q3 2025).